Back to homepage

Haematology and Oncology

Neonatal pharmacology and clinical implications

Authors: Antonio Ruggiero MD, Anna Ariano MD, Silvia Triarico MD, Michele Antonio Capozza MD, Pietro Ferrara MD, Giorgio Attinà MD

This review article analyses the main pharmacokinetic aspects (ADME) that exist during the neonatal period and offers a description of the physiological background for variability in pharmacological dosing.


Venetoclax: evidence to date and clinical potential

Authors: Luis Miguel Juárez-Salcedo MD, Viraj Desai BA, Samir Dalia MD

Thsi review article describes the mechanism of action that stands behind the efficacy of venetoclax and provides a summary of available results from clinical trials.


Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research

Authors: Stefania Nicola MD, Giovanni Rolla MD, Luisa Brussino MD

This review focuses on the mechanisms of action, routes of administration, and efficacy of therapies for the rare genetic disorder hereditary angioedema.


Standard care and investigational drugs in the treatment of myelofibrosis

Authors: Daniela Barraco MD, Margherita Maffioli MD, Francesco Passamonti MD

This article reviews the therapeutic landscape in myelofibrosis, which has
significantly improved, and emerging drugs with different
target pathways, alone or in combination with ruxolitinib.


Palbociclib in metastatic breast cancer: current evidence and real-life data

Authors: Francesco Serra MD, Pietro Lapidari MD, Erica Quaquarini MD, Barbara Tagliaferri MD, Federico Sottotetti MD, Raffaella Palumbo MD, PhD

This review summarizes the background and latest evidence for the use of palbociclib, an oral, first-in-class, highly selective cyclin-dependent kinase 4/6 inhibitor, in advanced breast cancer, with a focus on some of the unanswered questions about the performance of this agent in clinical practice.